Detection of omega-3 oxylipins in human plasma and response to treatment with omega-3 acid ethyl esters

Journal of Lipid Research

Volumn 51, Issue 8, 2010, Pages 2074-2081

  Shearer, Gregory C ^a   Harris, William S ^a   Pedersen, Theresa L ^b   Newman, John W ^b  

^a SANFORD RESEARCH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

DHA; EPA; Inflammation; Omega 3 fatty acid; P OM3

Indexed keywords

ALCOHOL; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; OXYLIPIN; ALCOHOL DERIVATIVE; EPOXIDE; ESTER; KETONE;

ADULT; ALCOHOL BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFICACY; DRUG MECHANISM; FATTY ACID ANALYSIS; FATTY ACID BLOOD LEVEL; FATTY ACID METABOLISM; FEMALE; HUMAN; MALE; NORMAL HUMAN; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; BLOOD; CHEMISTRY; CLINICAL TRIAL; DRUG EFFECTS; METABOLISM; MIDDLE AGED; TRANSPORT AT THE CELLULAR LEVEL; YOUNG ADULT;

ADULT; ALCOHOLS; BIOLOGICAL TRANSPORT; EPOXY COMPOUNDS; ESTERS; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; KETONES; MALE; MIDDLE AGED; OXYLIPINS; YOUNG ADULT;

EID: 77955689624     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/M900193-JLR200     Document Type: Article

References (41)

1. Harris, W. S., M. Miller, A. P. Tighe, M. H. Davidson, and E. J. Schaefer. 2008. Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis. 197: 12-24.
2. Calder, P. C. 2006. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am. J. Clin. Nutr. 83: 1505S-1519S.
3. Donadio, J. V., Jr., T. S. Larson, E. J. Bergstralh, and J. P. Grande. 2001. A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy. J. Am. Soc. Nephrol. 12: 791-799.
4. Samieri, C., C. Feart, L. Letenneur, J. F. Dartigues, K. Peres, S. Auriacombe, E. Peuchant, C. Delcourt, and P. Barberger-Gateau. 2008. Low plasma eicosapentaenoic acid and depressive symptomatology are independent predictors of dementia risk. Am. J. Clin. Nutr. 88: 714-721.
5. Lin, P. Y., and K. P. Su. 2007. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J. Clin. Psychiatry. 68: 1056-1061.
6. Sekikawa, A., J. D. Curb, H. Ueshima, A. El-Saed, T. Kadowaki, R. D. Abbott, R. W. Evans, B. L. Rodriguez, T. Okamura, K. Sutton-Tyrrell, et al. 2008. Marine-derived n-3 fatty acids and atherosclerosis in Japanese, Japanese-American, and white men: a cross-sectional study. J. Am. Coll. Cardiol. 52: 417-424.
7. Yamagishi, K., H. Iso, C. Date, M. Fukui, K. Wakai, S. Kikuchi, Y. Inaba, N. Tanabe, and A. Tamakoshi. 2008. Fish, omega-3 polyunsaturated fatty acids, and mortality from cardiovascular diseases in a nationwide community-based cohort of Japanese men and women the JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk) Study. J. Am. Coll. Cardiol. 52: 988-996.
8. Marchioli, R., F. Barzi, E. Bomba, C. Chieffo, D. Di Gregorio, R. Di Mascio, M. G. Franzosi, E. Geraci, G. Levantesi, A. P. Maggioni , et al . 2002 . Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation. 105: 1897-1903.
9. Tavazzi, L., A. P. Maggioni, R. Marchioli, S. Barlera, M. G. Franzosi, R. Latini, D. Lucci, G. L. Nicolosi, M. Porcu, and G. Tognoni. 2008. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 372: 1223-1230.
10. Harris, W. S., H. N. Ginsberg, N. Arunakul, N. S. Shachter, S. L. Windsor, M. Adams, L. Berglund, and K. Osmundsen. 1997. Safety and efficacy of Omacor in severe hypertriglyceridemia. J. Cardiovasc. Risk. 4: 385-391.
11. Leaf, A. 1995. Omega-3 fatty acids and prevention of ventricular fibrillation. Prostaglandins Leukot. Essent. Fatty Acids. 52: 197-198.
12. Shaikh, S. R., V. Cherezov, M. Caffrey, W. Stillwell, and S. R. Wassall. 2003. Interaction of cholesterol with a docosahexaenoic acid-containing phosphatidylethanolamine: trigger for microdomain/raft formation? Biochemistry. 42: 12028-12037.
13. Deckelbaum, R. J., T. S. Worgall, and T. Seo. 2006. n-3 fatty acids and gene expression. Am. J. Clin. Nutr. 83: 1520S-1525S.
14. Fleming, I. 2007. Epoxyeicosatrienoic acids, cell signaling and angiogenesis. Prostaglandins Other Lipid Mediat. 82: 60-67.
15. Honstra, G., A. C. van Houwelingen, G. A. Kivits, S. Fischer, and W. Uedelhoven. 1990. Influence of dietary fish on eicosanoid metabolism in man. Prostaglandins. 40: 311-329.
16. Larson, M. K., J. H. Ashmore, K. A. Harris, J. L. Vogelaar, J. V. Pottala, M. Sprehe, and W. S. Harris. 2008. Effects of omega-3 acid ethyl esters and aspirin, alone and in combination, on platelet function in healthy subjects. Thromb. Haemost. 100: 634-641.
17. Block, R. C., W. S. Harris, K. J. Reid, S. A. Sands, and J. A. Spertus. 2008. EPA and DHA in blood cell membranes from acute coronary syndrome patients and controls. Atherosclerosis. 197: 821-828.
18. Newman, J. W., G. A. Kaysen, B. D. Hammock, and G. C. Shearer. 2007. Proteinuria increases oxylipid concentrations in VLDL and HDL, but not LDL particles in the rat. J Lipid Res. 48: 1792-1800.
19. Luria, A., S. M. Weldon, A. K. Kabcenell, R. H. Ingraham, D. Matera, H. Jiang, R. Gill, C. Morisseau, J. W. Newman, and B. D. Hammock. 2007. Compensatory mechanism for homeostatic blood pressure regulation in Ephx2 gene-disrupted mice. J. Biol. Chem. 282: 2891-2898.
20. Dyerberg, J., H. O. Bang, E. Stoffersen, S. Moncada, and J. R. Vane. 1978. Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis? Lancet. 2: 117-119.
21. Leaf, A., J. X. Kang, Y. F. Xiao, and G. E. Billman. 2003. Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 fish oils. Circulation. 107: 2646-2652.
22. Fischer, S., and P. C. Weber. 1983. Thromboxane A3 (TXA3) is formed in human platelets after dietary eicosapentaenoic acid (C20:5 omega 3). Biochem. Biophys. Res. Commun. 116: 1091-1099.
23. Patel, P., C. Cossette, J. R. Anumolu, S. Gravel, A. Lesimple, O. A. Mamer, J. Rokach, and W. S. Powell. 2008. Structural requirements for activation of the 5-oxo-6E,8Z, 11Z,14Z-eicosatetraenoic acid (5-oxo-ETE) receptor: identification of a mead acid metabolite with potent agonist activity. J. Pharmacol. Exp. Ther. 325: 698-707.
24. Powell, W. S., S. Gravel, and F. Gravelle. 1995. Formation of a 5-oxo metabolite of 5,8,11,14,17-eicosapentaenoic acid and its effects on human neutrophils and eosinophils. J. Lipid Res. 36: 2590-2598.
25. Hughes, M. A., and A. R. Brash. 1991. Investigation of the mechanism of biosynthesis of 8-hydroxyeicosatetraenoic acid in mouse skin. Biochim. Biophys. Acta. 1081: 347-354.
26. Bolick, D. T., A. W. Orr, A. Whetzel, S. Srinivasan, M. E. Hatley, M. A. Schwartz, and C. C. Hedrick. 2005. 12/15-lipoxygenase regulates intercellular adhesion molecule-1 expression and monocyte adhesion to endothelium through activation of RhoA and nuclear factor-kappaB. Arterioscler. Thromb. Vasc. Biol. 25: 2301-2307.
27. Takata, S., A. Papayianni, M. Matsubara, W. Jimenez, P. H. Pronovost, and H. R. Brady. 1994. 15-Hydroxyeicosatetraenoic acid inhibits neutrophil migration across cytokine-activated endothelium. Am. J. Pathol. 145: 541-549.
28. Buchanan, M. R., P. Horsewood, and S. J. Brister. 1998. Regulation of endothelial cell and platelet receptor-ligand binding by the 12- and 15-lipoxygenase monohydroxides, 12-, 15-HETE and 13-HODE. Prostaglandins Leukot. Essent. Fatty Acids. 58: 339-346.
29. Xi, S., H. Pham, and V. A. Ziboh. 2000. Suppression of protooncogene (AP-1) in a model of skin epidermal hyperproliferation is reversed by topical application of 13-hydroxyoctadecadienoic acid and 15-hydroxyeicosatrienoic acid. Prostaglandins Leukot. Essent. Fatty Acids. 62: 13-19.
30. Node, K., Y. Huo, X. Ruan, B. Yang, M. Spiecker, K. Ley, D. C. Zeldin, and J. K. Liao. 1999. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science. 285: 1276-1279.
31. Schmelzer, K. R., L. Kubala, J. W. Newman, I. H. Kim, J. P. Eiserich, and B. D. Hammock. 2005. Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc. Natl. Acad. Sci. USA. 102: 9772-9777.
32. Fleming, I. 2004. Cytochrome P450 epoxygenases as EDHF synthase(s). Pharmacol. Res. 49: 525-533.
33. Xu, D., N. Li, Y. He, V. Timofeyev, L. Lu, H. J. Tsai, I. H. Kim, D. Tuteja, R. K. Mateo, A. Singapuri, et al. 2006. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc. Natl. Acad. Sci. USA. 103: 18733-18738.
34. Fang, X., S. Hu, B. Xu, G. D. Snyder, S. Harmon, J. Yao, Y. Liu, B. Sangras, J. R. Falck, N. L. Weintraub, et al. 2006. 14,15-Dihydroxy- eicosatrienoic acid activates peroxisome proliferator-activated receptor-alpha. Am. J. Physiol. Heart Circ. Physiol. 290: H55-H63.
35. Chinetti, G., J. C. Fruchart, and B. Staels. 2000. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm. Res. 49: 497-505.
36. Ye, D., D. Zhang, C. Oltman, K. Dellsperger, H. C. Lee, and M. VanRollins. 2002. Cytochrome p-450 epoxygenase metabolites of docosahexaenoate potently dilate coronary arterioles by activating large-conductance calcium-activated potassium channels. J. Pharmacol. Exp. Ther. 303: 768-776.
37. Shearer, G. C., and J. W. Newman. 2008. Lipoprotein lipase releases esterified oxylipins from very low-density lipoproteins. Prostaglandins Leukot. Essent. Fatty Acids. 79: 215-222.
38. Mackness, M. I., D. Bhatnagar, P. N. Durrington, H. Prais, B. Haynes, J. Morgan, and L. Borthwick. 1994. Effects of a new fish oil concentrate on plasma lipids and lipoproteins in patients with hypertriglyceridaemia. Eur. J. Clin. Nutr. 48: 859-865.
39. Calabresi, L., B. Villa, M. Canavesi, C. R. Sirtori, R. W. James, F. Bernini, and G. Franceschini. 2004. An omega-3 polyunsaturated fatty acid concentrate increases plasma high-density lipoprotein 2 cholesterol and paraoxonase levels in patients with familial combined hyperlipidemia. Metabolism. 53: 153-158.
40. Chan, D. C., G. F. Watts, P. H. Barrett, L. J. Beilin, T. G. Redgrave, and T. A. Mori. 2002. Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia. Diabetes. 51: 2377-2386.
41. Newman, J. W., G. A. Kaysen, B. D. Hammock, and G. C. Shearer. 2007. Proteinuria increases oxylipid concentrations in VLDL and HDL but not LDL particles in the rat. J. Lipid Res. 48: 1792-1800.